acut
respiratori
failur
common
reason
admiss
pediatr
intens
care
unit
oncolog
patient
acut
respiratori
complic
also
common
pediatr
hematopoiet
stem
cell
transplant
hsct
account
high
proport
hsctrelat
morbid
mortal
pulmonari
diseas
hsct
patient
progress
acut
respiratori
failur
often
requir
emerg
intub
support
invas
mechan
ventil
imv
mani
children
develop
refractori
hypoxemia
multiorgan
failur
tamburro
et
al
report
outcom
cohort
mechan
ventil
pediatr
oncolog
hsct
patient
nonhsct
patient
better
outcom
hsct
patient
surviv
outcom
better
oncolog
patient
nevertheless
wors
immunocompet
patient
immunocompromis
statu
chemotherapyrel
multiorgan
failur
like
complic
factor
affect
outcom
cohort
focus
complic
hsct
patient
intub
hsctrelat
acut
lung
injuri
ali
often
led
earli
redirect
care
due
high
fatal
two
decad
ago
recent
report
show
outcom
improv
improv
surviv
tamburro
et
al
demonstr
surviv
hsct
cohort
van
gestel
et
al
show
surviv
improv
outcom
like
multifactori
influenc
increas
willing
deliv
intens
care
therapi
earlier
rescu
support
innov
transplant
manag
lead
less
lung
toxic
acut
respiratori
failur
hypoxemia
due
inflamm
follow
known
clinic
insult
defin
acut
respiratori
distress
syndrom
ard
oncolog
hsct
patient
close
monitor
develop
pediatr
ard
pard
stratif
sever
ill
allow
earli
appropri
escal
respiratori
support
pediatr
acut
lung
injuri
consensu
confer
palicc
guidelin
defin
pard
stratifi
sever
use
follow
definit
lung
injuri
pediatr
oncolog
patient
relat
immunocompromis
statu
direct
pulmonari
toxic
chemotherapi
andor
radiat
chemotherapeut
agent
commonli
implic
lung
injuri
includ
bleomycin
cyclophosphamid
nitrosurea
cyclophosphamid
chlorambucil
methotrex
procarbazin
mitomycin
cytarabin
vinca
alkaloid
alkyl
agent
busulfan
bleomycin
busulfan
cyclophosphamid
nitrosurea
commonli
implic
pediatr
patient
toxic
radiat
therapi
dose
depend
patient
receiv
fraction
dose
less
risk
toxic
patient
receiv
total
dose
given
one
time
patient
typic
develop
symptom
within
month
receiv
radiat
therapi
present
cough
dyspnea
pinkting
sputum
inflammatori
phase
progress
fibrot
stage
progress
year
patient
phase
develop
increas
dyspnea
oxygen
requir
declin
pulmonari
function
test
toxic
chemotherapeut
agent
may
occur
earli
form
hypersensit
reaction
present
rale
fever
dyspnea
receiv
medic
patient
typic
respond
well
stop
medic
administr
steroid
endotheli
injuri
vascular
leak
caus
noncardiogen
pulmonari
edema
anoth
earli
pulmonari
toxic
seen
drug
methotrex
cytarabin
ifosfamid
cyclophosphamid
atra
transretino
acid
bleomycin
type
earli
toxic
respond
well
support
care
rel
good
prognosi
later
pulmonari
toxic
occur
sever
month
year
receiv
chemotherapeut
agent
lead
fibrot
lung
injuri
much
wors
prognosi
patient
respond
steroid
wean
steroid
occur
slowli
cautious
reactiv
underli
diseas
process
lung
injuri
occur
posthsct
patient
grossli
classifi
infecti
noninfecti
although
could
multifactori
patient
altern
pulmonari
complic
classifi
earli
late
classif
earli
late
within
beyond
day
respect
absolut
may
help
clinician
develop
differenti
diagnosi
earli
complic
tend
relat
immun
suppress
endotheli
alveolar
injuri
andor
neutrophil
recoveri
review
first
focu
earli
acut
complic
infecti
noninfecti
etiolog
later
address
late
complic
noninfecti
complic
hsct
often
treat
immun
suppress
therefor
first
step
manag
hsct
patient
acut
hypoxia
andor
hypercarbia
perform
thorough
workup
confirm
rule
infecti
etiolog
tabl
children
high
risk
death
infect
identifi
earli
treat
immun
dysregul
appropri
address
bacteri
viral
fungal
infect
consider
posttranspl
patient
given
immunosuppress
presenc
indwel
cathet
invas
line
identif
specif
organ
help
clinician
target
antimicrobi
therapi
unfortun
broadspectrum
empir
treatment
often
prolong
due
delay
turnaround
time
insensit
microbiolog
test
thought
bal
strongli
consid
patient
diffus
lung
injuri
posttranspl
howev
prudent
consid
riskbenefit
ratio
optim
time
bal
due
potenti
worsen
lung
mechan
triebwass
et
al
retrospect
chart
review
patient
differ
age
group
underw
bal
report
identif
pathogen
case
report
bal
led
chang
patient
manag
case
includ
alter
antibiot
immunosuppress
bal
complic
includ
hypoxemia
hemorrhag
respiratori
failur
patient
requir
mechan
ventil
prior
bal
would
suggest
earli
bal
would
safe
may
alter
treatment
plan
half
case
prophylaxi
preemptiv
screen
invas
fungal
cmv
infect
result
decreas
incid
posttranspl
improv
molecular
diagnost
techniqu
like
result
improv
test
yield
decreas
need
prolong
empir
therapi
infect
rule
children
lung
injuri
categor
either
acut
idiopath
pneumonia
syndrom
ip
engraft
syndrom
diffus
alveolar
hemorrhag
lung
injuri
syndrom
nation
institut
health
workshop
defin
ip
widespread
alveolar
injuri
absenc
activ
lower
respiratori
infect
cardiogen
caus
renal
failur
iatrogen
fluid
overload
hsct
definit
classifi
base
anatomi
interstiti
vascular
airway
tissu
unclassifi
tcellmedi
injuri
support
primari
pathophysiolog
murin
model
level
shown
increas
bal
fluid
mice
ip
support
clinic
observ
patient
receiv
tcelldeplet
graft
lower
incid
pulmonari
complic
howev
pathway
may
also
contribut
pathophysiolog
ip
given
pathwaymedi
injuri
solubl
protein
etanercept
test
trial
treatment
ip
earli
recognit
disord
rule
infecti
etiolog
initi
corticosteroid
along
antiinflammatori
target
therapi
may
improv
outcom
ip
engraft
syndrom
es
character
fever
rash
noncardiogen
pulmonari
edema
occur
time
neutrophil
recoveri
hsct
es
may
relat
graftversushost
respons
case
hostversusgraft
respons
chang
et
al
report
higher
risk
develop
gvhd
nonrelapserel
mortal
patient
es
corticosteroid
often
effect
patient
es
diffus
alveolar
hemorrhag
dah
origin
pulmonari
microvasculatur
respons
alveolar
injuri
may
noninfecti
etiolog
secondari
chemotherapi
radiat
immunemedi
event
system
pulmonari
infect
case
type
ip
progress
bloodi
return
note
bal
perform
highdos
corticosteroid
report
alter
outcom
patient
prospect
cohort
studi
adult
hsct
patient
howev
rathi
et
al
report
patient
receiv
lowdos
steroid
lower
mortal
comparison
mediumand
highdos
steroid
cohort
studi
adult
hsct
patient
wanko
et
al
report
decreas
mortal
versu
small
group
eight
adult
patient
dah
treat
concomit
aminocapro
acid
steroid
recombin
factor
viia
use
patient
refractori
bleed
shown
improv
durat
mechan
ventil
surviv
lung
injuri
syndrom
consid
includ
radiat
pneumon
pulmonari
venoocclus
diseas
pulmonari
cytolyt
thrombi
transfusionrel
acut
lung
injuri
pulmonari
arteri
hypertens
pulmonari
thromboembol
type
infect
identifi
influenc
patient
prognosi
treatment
hsct
patient
preemptiv
antivir
therapi
reduc
incid
cytomegaloviru
cmv
infect
hsct
ganciclovir
typic
use
treatment
cmv
infect
foscarnet
use
cytopenia
present
newer
drug
evalu
maribavir
letermovir
brincidofovir
adenoviru
caus
dissemin
infect
signific
mortal
hsct
patient
adenoviru
titer
serum
often
use
monitor
viral
load
respons
treatment
cidofovir
brincidofovir
use
treat
adenovir
infect
latter
demonstr
signific
nephrotox
respiratori
syncyti
viru
rsv
infect
immunocompromis
children
rapidli
progress
lower
respiratori
tract
infect
lower
respiratori
tract
infect
children
associ
mortal
attribut
rsv
recent
multicent
investig
report
low
incid
rsv
infect
posttranspl
patient
low
util
critic
care
servic
mortal
howev
note
patient
requir
critic
care
receiv
treatment
ribavirin
although
benefit
rigor
proven
popul
invas
fungal
infect
hsct
patient
associ
poor
outcom
abassi
et
al
report
mortal
within
first
year
diagnosi
aspergillu
infect
immunosuppress
pediatr
patient
howev
invas
fungal
infect
lung
decreas
better
antifung
prophylaxi
fungal
infect
also
often
requir
aggress
surgic
intervent
due
patient
underli
immunosuppress
pneumocysti
jiroveci
pneumonia
pjp
develop
pediatr
hsct
patient
without
prophylaxi
mortal
rate
higher
howev
rare
advent
routin
prophylaxi
bronchiol
obliteran
syndrom
bo
cryptogen
organ
pneumonia
cop
lateonset
noninfecti
pulmonari
complic
hsct
often
requir
chest
comput
tomographi
ct
lung
biopsi
make
diagnosi
bo
progress
obstruct
diseas
onset
month
posttranspl
patient
typic
present
wheez
dyspnea
chest
ct
may
demonstr
air
trap
centrilobular
nodul
bronchiectasi
histolog
demonstr
bronchiolar
inflamm
lumin
obstruct
cop
restrict
lung
diseas
onset
month
posttranspl
acut
onset
fever
cough
dyspnea
chest
ct
may
demonstr
patchi
airspac
diseas
nodular
opac
histolog
reveal
intralumin
organ
fibrosi
distal
airspac
mild
interstiti
inflamm
bo
cop
relat
tcellmedi
injuri
lung
epitheli
cell
initi
therapi
usual
highdos
corticosteroid
burst
prolong
taper
month
therapi
azithromycin
cyclosporin
etanercept
describ
need
evalu
recent
trial
inhal
fluticason
azithromycin
montelukast
patient
newonset
bronchiol
obliteran
show
combin
therapi
improv
abil
stabil
diseas
progress
compar
histor
control
transit
neg
pressur
ventil
posit
pressur
ventil
result
signific
chang
cardiopulmonari
interact
well
known
patient
mediastin
mass
imping
great
vessel
larg
pericardi
effus
maintain
spontan
ventil
use
special
equip
fiberopt
bronchoscop
avoid
use
paralyt
extracorpor
membran
oxygen
ecmo
equip
standbi
import
consider
transit
also
result
cardiopulmonari
collaps
patient
right
heart
failur
patient
intravascularli
deplet
patient
septic
shock
hypovolem
shock
former
may
seen
due
cardiac
toxic
chemotherapi
andor
radiat
pulmonari
hypertens
optim
intravascular
volum
use
inotrop
augment
ventricular
function
avail
inhal
nitric
oxid
avert
pulmonari
hypertens
crisi
might
help
prevent
need
cardiopulmonari
resuscit
transit
endotrach
intub
associ
mani
complic
highest
concern
ventil
associ
pneumonia
noninvas
posit
pressur
ventil
consist
continu
posit
airway
pressur
cpap
bilevel
posit
airway
pressur
bipap
modal
assist
oxygen
ventil
patient
respiratori
distress
acut
respiratori
failur
potenti
avoid
complic
invas
mechan
ventil
imv
continu
posit
airway
pressur
cpap
maintain
posit
pressur
prevent
airway
alveolar
collaps
patient
spontan
breath
bipap
trigger
patient
breath
inspiratori
posit
airway
pressur
ipap
provid
prevent
airway
alveolar
collaps
expiratori
posit
airway
pressur
epap
respiratori
rate
also
set
bipap
sometim
lead
dysynchroni
mandatori
breath
patient
innat
respiratori
effort
niv
potenti
allow
avoid
intub
imv
certain
clinic
scenario
consid
contraind
use
niv
contraind
relat
patient
inabl
protect
airway
risk
aspir
worsen
gastric
distens
andor
inabl
provid
consist
intrathorac
posit
pressur
associ
risk
contraind
niv
use
list
follow
high
risk
respiratori
cardiac
arrest
hemodynam
instabl
dysrhythmia
shock
absent
weak
cough
gag
inabl
protect
airway
glasgow
coma
score
rapidli
progress
neuromuscular
weak
inabl
good
mask
fit
facial
surgeri
trauma
burn
etc
untreat
pneumothorax
vomit
risk
aspir
poor
skin
integr
lead
skin
breakdown
much
niv
data
avail
immunocompromis
patient
dearth
data
specif
hematopoiet
stem
cell
transplant
hsct
patient
niv
shown
adult
studi
reduc
intub
rate
shorten
icu
length
stay
reduc
cost
hospit
metaanalysi
wang
et
al
look
niv
versu
imv
immunocompromis
patient
icu
length
stay
significantli
shorter
niv
group
howev
patient
lower
sever
ill
score
addit
group
found
signific
decreas
hospit
mortal
niv
group
compar
imv
group
though
high
degre
heterogen
within
hematolog
solid
tumor
subgroup
mortal
significantli
reduc
ci
niv
compar
imv
similarli
retrospect
review
immunocompromis
pediatr
patient
receiv
niv
pancera
et
al
found
niv
group
higher
probabl
surviv
compar
imv
howev
patient
imv
group
marker
higher
ill
sever
evidenc
two
organ
failur
cardiovascular
dysfunct
therapeut
intervent
score
system
score
niv
uniformli
success
grow
bodi
evid
aim
determin
factor
lead
failur
modal
atrisk
popul
literatur
report
niv
success
rate
immunocompromis
pediatr
patient
diagnosi
acut
respiratori
distress
syndrom
diagnosi
respiratori
failur
among
patient
acut
respiratori
failur
receiv
niv
fio
h
initi
predict
failur
niv
within
pediatr
immunocompromis
patient
fail
niv
like
sever
sepsi
septic
shock
success
group
patient
niv
success
group
earli
sustain
improv
compar
fail
therefor
lack
earli
improv
discuss
threshold
improv
h
h
munozbonet
et
al
determin
improv
respiratori
rate
pco
h
niv
associ
niv
success
patient
improv
pao
fio
ratio
within
first
hour
niv
initi
also
like
niv
success
group
therefor
lack
improv
physiolog
paramet
wean
decreas
respiratori
rate
within
h
niv
initi
consid
indic
endotrach
intub
fig
addit
appear
prudent
consid
patient
escal
hemodynam
support
fail
niv
trial
niv
associ
pressurerel
painskin
breakdown
due
face
mask
strap
extrem
may
necessit
intub
address
earli
niv
requir
synchroni
patient
ventil
without
patient
may
also
fail
niv
howev
littl
mention
literatur
niv
also
use
palli
care
situat
allevi
air
hunger
adult
studi
shown
decreas
dyspnea
reduc
amount
morphin
use
niv
viabl
method
oxygen
ventil
immunocompromis
patient
respiratori
failur
howev
controversi
exist
use
niv
patient
acut
respiratori
failur
due
potenti
prolong
time
intub
ultim
lead
wors
outcom
therefor
import
understand
niv
potenti
avoid
complic
imv
util
requir
constant
monitor
patient
ensur
improv
lack
physiolog
improv
consid
indic
endotrach
intub
provid
would
reason
patient
underli
diseas
consist
goal
care
outlin
famili
mortal
respiratori
failur
pediatr
oncolog
hsct
patient
vari
depend
underli
clinic
diagnosi
etiolog
tamburro
et
al
report
overal
surviv
extub
discharg
mechan
ventil
pediatr
oncolog
patient
hsct
patient
aspesberro
et
al
cite
surviv
month
pediatr
hsct
patient
mechan
ventil
reason
intub
elect
procedur
emerg
due
lung
failur
degre
lung
injuri
import
consid
given
high
mortal
import
urgent
rediscuss
goal
care
code
statu
patient
irrevers
underli
diseas
month
less
live
may
prolong
suffer
multicent
retrospect
cohort
studi
hsct
patient
picu
mortal
note
patient
ventil
longer
day
time
higher
odd
death
patient
place
highfrequ
oscillatori
ventil
hfov
higher
mortal
transit
hfov
within
day
start
invas
mechan
ventil
result
decreas
odd
death
compar
transit
later
studi
suggest
earli
aggress
lung
protect
ventil
strategi
may
result
improv
outcom
patient
hypoxem
respiratori
failur
common
reason
hypoxemia
like
alveolar
derecruit
optim
alveolar
recruit
use
adequ
posit
end
expiratori
pressur
peep
limit
peak
inspiratori
pressur
pip
therebi
avoid
ventilatorinduc
lung
injuri
vili
goal
invas
mechan
ventil
permiss
hypercapnia
hypoxia
ensur
adequ
endorgan
oxygen
deliveri
would
help
achiev
goal
patient
sever
lung
injuri
intub
patient
hypoxem
respiratori
failur
estim
use
oi
osi
oi
shown
also
predictor
mortal
oi
point
ventil
posttranspl
patient
shown
associ
mortal
oi
associ
mortal
consist
optim
lung
recruit
prevent
ventilatorinduc
lung
injuri
pediatr
acut
lung
injuri
consensu
confer
palicc
guidelin
recommend
util
moder
elev
level
peep
titrat
observ
oxygen
hemodynam
respons
recommend
tidal
volum
mlkg
ideal
bodi
weight
base
respiratori
system
complianc
high
peep
level
may
requir
children
larg
abdomin
mass
ascit
caus
signific
mechan
constraint
diaphragm
interf
lung
mechan
caus
signific
lung
derecruit
palicc
guidelin
recommend
consider
hfov
plateau
pressur
exceed
cm
h
therebi
one
abl
achiev
lung
recruit
without
util
high
ventil
strategi
one
consid
escal
nonconvent
modal
consid
lung
protect
airway
pressur
releas
ventil
aprv
anoth
modal
use
center
rowan
et
al
retrospect
multicent
databas
studi
report
pediatr
hsct
patient
sever
pard
manag
hfov
studi
suggest
cohort
earli
use
hfov
associ
improv
surviv
compar
late
implement
hfov
subject
outcom
similar
treat
convent
mechan
ventil
continu
need
outcom
data
hfov
aprv
use
pediatr
patient
respiratori
failur
yehya
et
al
cohort
pediatr
patient
refractori
convent
mechan
ventil
requir
transit
hfov
aprv
demonstr
hfov
associ
frequent
neuromuscular
blockad
differ
mortal
perhap
import
observ
improv
oi
h
transit
hfov
aprv
associ
surviv
like
reflect
sever
lung
diseas
andor
abil
rerecruit
lung
conclus
lung
protect
ventil
implement
earli
cohort
children
given
high
risk
mortal
morbid
pediatr
oncolog
hsct
patient
sever
pard
evalu
possibl
ecmo
support
lung
protect
strategi
result
inadequ
ga
exchang
immunocompromis
statu
demonstr
independ
risk
factor
hospit
mortal
adult
patient
respiratori
failur
ecmo
establish
set
criteria
ecmo
cannul
popul
challeng
given
immunocompromis
statu
thrombocytopenia
uniquevari
rang
patholog
multiorgan
dysfunct
gow
et
al
report
surviv
rate
decannul
small
cohort
pediatr
hsct
patient
renal
complic
multiorgan
dysfunct
report
risk
factor
death
therebi
appear
prudent
make
decis
regard
cannul
util
multidisciplinari
approach
earli
diseas
process
determin
candidaci
time
cannul
allow
serial
evalu
patient
famili
appropri
counsel
inform
consent
obtain
prior
ecmo
cannul
given
high
risk
complic
patient
popul
fluid
overload
common
hsct
patient
develop
pard
initi
empir
broadspectrum
antimicrobi
treatment
often
exacerb
situat
tight
fluid
manag
imper
along
initi
diuret
mani
patient
clinic
order
limit
total
fluid
mainten
concentr
medic
infus
evalu
need
medic
high
volum
fluid
done
earli
avoid
worsen
fluid
overload
acut
renal
failur
uncommon
complic
posttranspl
patient
make
fluid
manag
extrem
challeng
fluid
overload
associ
acut
renal
failur
lead
worsen
respiratori
function
prolong
ventil
increas
icu
stay
mortal
earli
consult
renal
specialist
intervent
diuret
advanc
therapi
fluid
remov
imper
retrospect
chart
review
critic
ill
pediatr
patient
receiv
continu
venoven
hemofiltr
median
fluid
overload
percentag
significantli
lower
survivor
versu
nonsurvivor
vs
michael
et
al
review
hsct
patient
acut
renal
failur
note
fluid
overload
associ
improv
surviv
ellbahlawan
et
al
demonstr
signific
improv
ratio
hsct
patient
initi
continu
renal
replac
therapi
significantli
correl
reduct
fluid
balanc
initi
crrt
treatment
fluid
overload
may
improv
oxygen
surviv
use
inhal
nitric
oxid
consid
patient
document
pulmonari
hypertens
sever
right
ventricular
dysfunct
palicc
guidelin
also
recommend
consider
use
rescu
bridg
ecmo
surfact
use
immunocompromis
children
acut
lung
injuri
associ
improv
oxygen
post
hoc
analysi
data
previou
random
control
trial
subsequ
fdafund
multicent
trial
attempt
investig
util
surfact
cohort
unfortun
stop
due
low
enrol
therefor
remain
lack
evid
support
efficaci
surfact
use
patient
popul
immunocompromis
oncolog
patient
includ
hsct
patient
uniqu
patient
popul
uniqu
patholog
organ
dysfunct
lead
respiratori
failur
evalu
hsct
patient
acut
hypoxia
andor
hypercarbia
requir
workup
confirm
rule
infecti
etiolog
prior
treatment
potenti
noninfecti
caus
util
niv
requir
constant
monitor
patient
ensur
improv
lack
physiolog
improv
niv
consid
indic
endotrach
intub
earli
aggress
lung
protect
ventil
strategi
upon
intub
close
monitor
fluid
overload
may
result
improv
outcom
patient
research
requir
look
modifi
clinic
factorsmanag
techniqu
assess
outcom
use
niv
imv
ecmo
uniqu
popul
